Table 3.
Tumor characteristics of interval breast cancers
| A SFM with prior SFM |
B FFDM with prior SFM |
C FFDM with prior FFDM |
|
|---|---|---|---|
| Ductal carcinoma in-situ | |||
| Grade, n (%) | |||
| Low | 2 (25.0) | 3 (33.3) | 1 (12.5) |
| Intermediate | 2 (25.0) | 3 (33.3) | 3 (37.5) |
| High | 4 (50.0) | 3 (33.3) | 4 (50.0) |
| Invasive cancer | |||
| Type, n (%) | |||
| Ductal | 103 (75.7)* | 117 (78.0)† | 88 (67.2) |
| Lobular | 23 (16.9) | 19 (12.7) | 28 (21.4) |
| Mixed ductal/lobular | 7 (5.1) | 7 (4.7) | 7 (5.3) |
| Other | 3 (2.2) | 7 (4.7) | 8 (6.1) |
| Stage, n (%) | |||
| T1a-c | 66 (48.5) | 70 (46.7) | 59 (45.0) |
| T2+ | 70 (51.5) | 78 (52.0) | 68 (51.9) |
| Unknown | 0 (0.0) | 2 (1.3) | 4 (3.1) |
| Lymph node status, n (%) | |||
| N+ | 62 (45.6) | 63 (42.0) | 54 (41.2) |
| No | 73 (53.7) | 84 (56.0) | 73 (55.7) |
| Unknown | 1 (0.7) | 3 (2.0) | 4 (3.1) |
| Bloom & Richardson grade, n (%) | |||
| I | 44 (32.4) | 38 (25.3) | 33 (25.2) |
| II | 57 (41.9) | 77 (51.3) | 68 (51.9) |
| III | 31 (22.8) | 30 (20.0) | 29 (22.1) |
| Unknown | 4 (2.9) | 5 (3.3) | 1 (0.8) |
| Estrogen receptor, n (%) | |||
| Positive | 101 (74.3) | 123 (82.0) | 106 (80.9) |
| Negative | 35 (25.7) | 27 (18.0) | 25 (19.1) |
| Progesteron receptor, n (%) | |||
| Positive | 74 (54.4) | 87 (58.0) | 76 (58.0) |
| Negative | 62 (45.6) | 63 (42.0) | 55 (42.0) |
| Her2/Neu receptor, n (%) | |||
| Positive | 19 (14.0) | 22 (14.7) | 14 (10.7) |
| Negative | 116 (85.3) | 127 (84.7) | 117 (89.3) |
| Unknown | 1 (0.7) | 1 (0.7) | 0 (0.0) |
| Triple receptor-negative, n (%) | 25 (18.5) | 21 (14.0) | 17 (13.0) |
* significantly different from C (p < 0.05)
† significantly different from C (p < 0.01)